Curanex Pharmaceuticals (CURX) Total Liabilities (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly Total Liabilities came in at $361040.0 in Q4 2025, up 2377.12% YoY from $14575.0 in Q4 2024, and up 94.15% on a QoQ basis from $185955.0 in Q3 2025.
Curanex Pharmaceuticals (CURX) Total Liabilities (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of Total Liabilities data on file, last reported at $361040.0 in Q4 2025.
- Quarterly Total Liabilities rose 2377.12% year-over-year to $361040.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $361040.0 (up 2377.12% YoY) and the FY2025 annual result came in at $361040.0, up 2377.12% from the prior year.
- Total Liabilities grew to $361040.0 in Q4 2025, from $185955.0 in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $481743.0 in Q2 2025 to a low of $14575.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Curanex Pharmaceuticals | 6.11 Mn | 1.11 Mn | - | 361,040.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 361,040.00 |
| Sep 30, 2025 | 185,955.00 |
| Jun 30, 2025 | 481,743.00 |
| Dec 31, 2024 | 14,575.00 |